AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26052677 — intervention group
Group type: COMPARATOR
Intervention: MPI
Number of subjects: 400
Study 23057804 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (10 mg/kg on day 1, 5 mg/kg on day 2, and 5 mg/kg on day 3)
Number of subjects: 134
Study 23057804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 21749238 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-intervention condition (n = 188)
Number of subjects: 348
Study 21749238 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 160)
Number of subjects: 348
Study 19488539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% racemic bupivacaine with vasoconstrictor
Number of subjects: 50
Study 19488539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% enantiomeric excess bupivacaine (S75-R25) with vasoconstrictor
Number of subjects: 50
Study 19488539 — intervention group
Group type: COMPARATOR
Intervention: Both groups (0.5% racemic bupivacaine and 0.5% enantiomeric excess bupivacaine)
Number of subjects: 50
Study 17004191 — intervention group
Group type: EXPERIMENTAL
Intervention: Repithel
Number of subjects: 167
Study 17004191 — intervention group
Group type: COMPARATOR
Intervention: Lipid gauze alone (Control)
Number of subjects: 167
Study 12724244 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 193
Study 12724244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 193
Study 12724244 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 193
Study 12724244 — intervention group
Group type: COMPARATOR
Intervention: Routine primary care
Number of subjects: 193
Study 11085197 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 0
Study 11085197 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study 11085197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8756195 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic drainage (cistofix Ch 15)
Number of subjects: 52
Study 8756195 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheterization (latex foley catheter)
Number of subjects: 52
Study 1826912 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/d)
Number of subjects: 20
Study 1826912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/d)
Number of subjects: 20
Study 6628498 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2-16 mg)
Number of subjects: 20
Study 6628498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (0.2-1.6 mg)
Number of subjects: 20
Study 6628498 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 31292608 — intervention group
Group type: EXPERIMENTAL
Intervention: levcromakalim (0.05 mg/min)
Number of subjects: 16
Study 31292608 — intervention group
Group type: EXPERIMENTAL
Intervention: levcromakalim
Number of subjects: 16
Study 31292608 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 28203319 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (37 mg of elemental iron daily for 3 weeks)
Number of subjects: 25
Study 28203319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28203319 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 25
Study 25791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron administered as a single oral dose under fasted conditions.
Number of subjects: 0
Study 25791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron administered once daily under fed conditions for 8 days after a washout period.
Number of subjects: 0
Study 25791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron administered with low-fat and high-fat meals.
Number of subjects: 0
Study 25791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron in female subjects compared to male subjects.
Number of subjects: 0
Study 25791612 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and tolerability assessments of mirabegron.
Number of subjects: 0
Study 23299853 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm A
Number of subjects: 301
Study 23299853 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm B
Number of subjects: 301
Study 23299853 — intervention group
Group type: COMPARATOR
Intervention: Control arm (C)
Number of subjects: 301
Study 21174007 — intervention group
Group type: EXPERIMENTAL
Intervention: γ' fibrinogen levels
Number of subjects: 284
Study 21174007 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 284
Study 21174007 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of dental sites with tissue inflammation
Number of subjects: 284
Study 21174007 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fibrinogen levels
Number of subjects: 284
Study 19245306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (cooling to 35 degrees C and 33 degrees C)
Number of subjects: 240
Study 19245306 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (standard management at normothermia)
Number of subjects: 240
Study 17348435 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 0
Study 17348435 — intervention group
Group type: COMPARATOR
Intervention: Control (blood transfusions)
Number of subjects: 0
Study 14679118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (25 mg/m²) and Docetaxel (20 mg/m²) administered on days 1, 8, and 15 every 4 weeks
Number of subjects: 34
Study 14679118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Docetaxel
Number of subjects: 34
Study 11354452 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional scrubbing of toe clefts with a gauze swab soaked in topical antiseptic.
Number of subjects: 50
Study 11354452 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation with antiseptic between the toes.
Number of subjects: 50
Study 9075034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-orifice epidural catheters
Number of subjects: 872
Study 9075034 — intervention group
Group type: COMPARATOR
Intervention: Single-orifice epidural catheters
Number of subjects: 872
Study 7905101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of 17 beta‐oestradiol
Number of subjects: 18
Study 7905101 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch administration of 17 beta‐oestradiol
Number of subjects: 18
Study 7905101 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of oestradiol
Number of subjects: 18
Study 3139909 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg Euphyllin (theophylline)
Number of subjects: 30
Study 3139909 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg Euphyllin (theophylline)
Number of subjects: 30
Study 31490025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic DNA methylation biomarkers identified through RNA-seq analysis, including 567 CpG sites related to overall survival (OS) and 1,146 CpG site pairs related to OS.
Number of subjects: 0
Study 31490025 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation dataset for prognostic signatures.
Number of subjects: 0
Study 31490025 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-protein interactions (PPI) network analysis of the CpG sites of the signature.
Number of subjects: 0
Study 31060536 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose alarm strategy
Number of subjects: 21
Study 31060536 — intervention group
Group type: COMPARATOR
Intervention: Tight alarm strategy
Number of subjects: 21
Study 28800341 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training with anodal tDCS
Number of subjects: 21
Study 28800341 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study 26292584 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 795
Study 26292584 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (AVR)
Number of subjects: 795
Study 22906685 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (1 mg/h)
Number of subjects: 9
Study 22906685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21707215 — intervention group
Group type: EXPERIMENTAL
Intervention: Gist-based reasoning triggered by retrieval cues
Number of subjects: 0
Study 21707215 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbatim-based reasoning triggered by different retrieval cues
Number of subjects: 0
Study 19085404 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 312
Study 19085404 — intervention group
Group type: COMPARATOR
Intervention: High-quality train-and-place vocational rehabilitation (Control)
Number of subjects: 312
Study 19085404 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 312
Study 16490028 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemic response (RHR) measurement in ED patients with concomitant CVD or risk factors
Number of subjects: 48
Study 16490028 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemic response (RHR) measurement in ED patients without CVD or risk factors
Number of subjects: 48
Study 16490028 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study 12560299 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 20 microg x kg(‐1), lidocaine 1.5 mg x kg(‐1), propofol 3 mg x kg(‐1) (Group I; n = 40)
Number of subjects: 80
Study 12560299 — intervention group
Group type: COMPARATOR
Intervention: fentanyl 2 microg x kg(‐1), lidocaine 1.5 mg x kg(‐1), propofol 3 mg x kg(‐1) (Group II; n = 40)
Number of subjects: 80
Study 12560299 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 80
Study 12560299 — intervention group
Group type: COMPARATOR
Intervention: Group II
Number of subjects: 80
Study 10716371 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 microg of the lipopeptide immunogen administered on days 0, 28, and 56 to HLA-selected subjects (4 subjects)
Number of subjects: 9
Study 10716371 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered according to a similar inoculation schedule to HLA-selected subjects (3 subjects)
Number of subjects: 9
Study 10716371 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 microg of the lipopeptide immunogen administered to HLA-mismatched subjects (2 subjects)
Number of subjects: 9
Study 9179102 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine individual feedback on test ordering behavior
Number of subjects: 0
Study 9179102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 8231034 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 degrees C dialysate
Number of subjects: 12
Study 8231034 — intervention group
Group type: COMPARATOR
Intervention: 37 degrees C dialysate
Number of subjects: 12
Study 3544940 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg body weight diazepam (Group A)
Number of subjects: 20
Study 3544940 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg/kg body weight midazolam (Group B)
Number of subjects: 20
Study 27491344 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (ten sets of 2‐min walking at the speed corresponding to the onset of claudication pain with 2‐min interval between sets)
Number of subjects: 13
Study 27491344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (1 × 10 reps in eight resistance exercises plus five‐two‐minute sets of walking)
Number of subjects: 13
Study 26829083 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month home physiotherapy program
Number of subjects: 48
Study 26829083 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 23887332 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced exercise program
Number of subjects: 54
Study 23887332 — intervention group
Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 54
Study 22802599 — intervention group
Group type: EXPERIMENTAL
Intervention: bisGMA-based composite
Number of subjects: 534
Study 22802599 — intervention group
Group type: COMPARATOR
Intervention: compomer
Number of subjects: 534
Study 22802599 — intervention group
Group type: COMPARATOR
Intervention: amalgam
Number of subjects: 534
Study 20354032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 2622
Study 17391383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin-clavulanic acid 625 mg, four times daily for 3 days
Number of subjects: 56
Study 17391383 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin-clavulanic acid 625 mg, four times daily for 10 days
Number of subjects: 56
Study 17391383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 56
Study 16141426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole/Aspirin (200 mg dipyridamole/25 mg aspirin twice a day)
Number of subjects: 6
Study 16141426 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (control)
Number of subjects: 6
Study 16141426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole/Aspirin
Number of subjects: 6
Study 12164990 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate/xylitol gum (ACHX)
Number of subjects: 111
Study 12164990 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum (X)
Number of subjects: 111
Study 12164990 — intervention group
Group type: COMPARATOR
Intervention: No-gum (N)
Number of subjects: 111
Study 10457579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mensendieck exercise program
Number of subjects: 77
Study 10457579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 8545530 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 60
Study 8545530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study 2349370 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 38
Study 2349370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 38
Study 215011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of double stranded RNA from f2-phage
Number of subjects: 0
Study 215011 — intervention group
Group type: COMPARATOR
Intervention: Double-blind experiment
Number of subjects: 0
Study 31626006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use during TKA
Number of subjects: 200
Study 31626006 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet use during TKA
Number of subjects: 200
Study 28364615 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum strength (STR)
Number of subjects: 22
Study 28364615 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle endurance (END)
Number of subjects: 22
Study 28364615 — intervention group
Group type: COMPARATOR
Intervention: Control (M-BEAST)
Number of subjects: 22
Study 25693055 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids for ∼9 months and a maximum of six 500‐mg fixed‐dose intravenous (IV) cyclophosphamide (CYC) pulses, every 2‐3 weeks, then maintenance azathioprine or methotrexate.
Number of subjects: 108
Study 25693055 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids for ∼26 months combined with 500 mg/m2 IV CYC pulses, every 2‐3 weeks until remission, then maintenance for GPA or MPA patients and for those with EGPA or PAN with a Five‐Factors Score (FFS) of ≥1.
Number of subjects: 108
Study 23457086 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational self-efficacy
Number of subjects: 373
Study 23457086 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional self-efficacy
Number of subjects: 373
Study 21762149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Number of subjects: 0
Study 21762149 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional clinical indices (Modified Gingival Index and Bleeding Index)
Number of subjects: 0
Study 21762149 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impressions for gingival contour volume measurement
Number of subjects: 0
Study 21762149 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 19873911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Baihui (GV 20), Danzhong (CV 17), Zhongwan (CV 12), Qihai (CV 6), Guanyuan (CV 4), Hegu (LI 4), Zusanli (ST 36), thrice a week for 14 sessions
Number of subjects: 70
Study 19873911 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non-meridian points (2 cm to the acupoints), thrice a week for 14 sessions
Number of subjects: 70
Study 17761637 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga program
Number of subjects: 68
Study 17761637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 15513324 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cardiac troponin T (cTnT)
Number of subjects: 26
Study 11179125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose of salbutamol (400 microg)
Number of subjects: 24
Study 11179125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose of salbutamol (800 microg)
Number of subjects: 24
Study 11179125 — intervention group
Group type: COMPARATOR
Intervention: Single dose of salbutamol (50, 100, or 400 microg)
Number of subjects: 24
Study 11179125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose of salbutamol (50+50+100+200 or 100+100+200+400 or 400+0+0+0 or 0+0+0+0 microg)
Number of subjects: 24
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation after biopsy/local excision
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation after partial/radical vulvectomy
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation with doses under 50 Gy in T1-2 tumors
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation with doses below 50 Gy in T3-4 tumors
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation after partial/radical vulvectomy in T1-2 tumors
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation after partial/radical vulvectomy in T3-4 tumors
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation after partial or radical lymph node dissection
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of irradiation and wide local tumor excision
Number of subjects: 86
Study 9788413 — intervention group
Group type: EXPERIMENTAL
Intervention: Postradical vulvectomy irradiation
Number of subjects: 86
Study 8141197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel 5 gm twice daily for 5 days
Number of subjects: 90
Study 8141197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8141197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 90
Study 3142242 — intervention group
Group type: EXPERIMENTAL
Intervention: Max EPA intake in coronary artery disease patients
Number of subjects: 12
Study 3142242 — intervention group
Group type: EXPERIMENTAL
Intervention: Max EPA intake in normal subjects
Number of subjects: 12
Study 31556911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib s-maleate
Number of subjects: 119
Study 31556911 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone hydrochloride-prednisone
Number of subjects: 119
Study 29852887 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CDQ scores for non-core foods (indicating higher consumption levels)
Number of subjects: 396
Study 29852887 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported subscale score for fruit and vegetable intake
Number of subjects: 396
Study 29852887 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported subscale score for non-core food intake
Number of subjects: 396
Study 27707496 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, goal-directed mobilisation
Number of subjects: 200
Study 27707496 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 200
Study 25973554 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 38
Study 25973554 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 22907796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ice pack application
Number of subjects: 18
Study 22907796 — intervention group
Group type: COMPARATOR
Intervention: Room temperature packs
Number of subjects: 18
Study 19758358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine and individualized weight management
Number of subjects: 10742
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of fruit and vegetable recommendations
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of change (action vs contemplation/preparation)
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived health benefits
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily servings of fruit and vegetable intake
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of fruit and vegetable recommendations
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of colorful variety importance
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of serving size
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of fiber source
Number of subjects: 490
Study 18656571 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of vitamin pills
Number of subjects: 490